KOD - NASDAQ
Kodiak Sciences Inc.
$33.87
-8.2%Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
At a Glance
Live SnapshotKodiak Sciences Inc. Management Team
Dr. J. Pablo Velazquez-Martin M.D.
Chief Medical Officer
Ms. Almas Qudrat M.Sc.
Chief Quality Officer
Dr. Dolly S. Chang M.D., M.P.H., Ph.D.
Chief Scientific Officer
Dr. Victor Perlroth M.D.
Co-Founder, Chairman, Chief Executive Officer & President
Compensation
$1,308,492
Mr. John A. Borgeson CPA, M.B.A.
Executive Vice President, Chief Financial Officer & Secretary
Compensation
$795,799
Dr. Laurent Ducay Ph.D.
Senior Vice President of Biologics Development & Manufacturing
Dr. Stephen Raillard Ph.D.
Senior Vice President of Chemical Development & Manufacturing
Dr. Hong Liang Ph.D.
Senior Vice President of Development
Compensation
$300,709
Kodiak Sciences Inc. Insider Positioning
During the last 12 months, insiders have purchased $58.22M and sold $499K worth of KOD shares, resulting in $57.73M of net buying activity.
3 Months
0
0.00
12.7K
496.76K
-497K
-$497K
3-6 Months
2.4M
55.00M
0
0.00
+55.0M
+$55.00M
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
830.0K
3.23M
723
2.64K
+3.2M
+$3.22M
Top Buyers
Baker Bros. Advisors Lp
Director, 10 Percent Owner:
$55.15M
Perlroth Victor
Director, 10 Percent Owner, Officer: Chairman And Ceo
$1.34M
Borgeson John A.
Officer: See Remarks
$988K
Dahiyat Bassil I
Director
$149K
Levy Richard S
Director
$149K
Top Sellers
Borgeson John A.
Officer: Chief Financial Officer
$499K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $57.73M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
KOD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 22, 2026 | June 02, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 22, 2025 | June 02, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 23, 2024 | June 04, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 25, 2023 | June 06, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 28, 2022 | June 07, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | September 13, 2021 | October 13, 2021 | 2021 | |
DEF 14A DEF 14A 2021 N/A | April 28, 2021 | June 07, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 29, 2020 | June 08, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 24, 2019 | June 03, 2019 | 2019 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.